Recurrent CYP2C19 deletion allele is associated with triple-negative breast cancer

BMC Cancer

Table 2 Tumor characteristics of CYP2C19 deletion allele carriers compared with the tumors of non-carrier unselected breast cancer cases

Category	CYP2C19deletion	%	Wild type	%	P-value^a	OR	95% CI
T
1	18	62.0%	304	58.3%
2	10	34.5%	188	36.1%	0.692	1.17	0.54-2.52
3	1	3.5%	16	3.1%	1 vs. 2,3,4
4	0	0%	13	2.5%
N
Neg	20	64.5%	293	56.0%	0.354	1.43	0.67-3.04
Pos	11	35.5%	230	44.0%
M
Neg	31	100%	500	95.6%	0.632	NA
Pos	0		23	4.4%
ER
Neg	10	34.5%	101	19.3%	0.048	2.19	0.99-4.86
Pos	19	65.5%	421	80.7%
PR
Neg	13	44.8%	153	29.4%	0.078	1.95	0.92-4.16
Pos	16	55.2%	368	70.6%
HER2
Neg	24	82.8%	447	85.6%	0.595	0.81	0.30-2.18
Pos	5	17.2%	75	14.4%
Grade
1	4	12.9%	86	17.1%
2	14	45.2%	226	44.9%	0.659	0.85	0.41-1.77
3	13	41.9%	191	38.0%	1 and 2 vs. 3
Tumor histology
Ductal	23	79.2%	395	75.7%
Lobular	3	10.4%	90	17.2%	0.656	1.23	0.49-3.09
Medullary	0	0%	2	0.4%	Ductal vs. all other
Other	3	10.4%	35	6.7%
Type
LumA	16	55.2%	385	73.8%
LumB	3	10.3%	43	8.2%	0.021	2.83	1.20-6.66
HER2	2	6.9%	32	6.1%	Triple-neg vs. other
Triple-neg	8	27.6%	62	11.9%
Ki67
0	1	3.6%	71	13.7%
1	13	46.4%	231	44.5%	0.393	0.72	0.34-1.54
2	7	25.0%	112	21.6%	0 and 1 vs. 2 and 3
3	7	25.0%	105	20.2%

T = tumor size, N = nodal status, M = primary metastasis, ER = estrogen receptor, PR = progesterone receptor, LumA = luminalA, LumB = luminalB, Neg = negative, Pos = positive.
^anot corrected for multiple testing.

ISSN: 1471-2407